Observe aseptic technique & standard practice to prevent cross-infections. Should only be used in the deep dermis or SC layer. Avoid improper inj techniques to avoid appearance of papules or nodules at the inj site. Massage the treatment area to ensure proper distribution of the product. Do not inj IM or intravascularly. Exercise special caution if patient has undergone prior surgical procedure in the planned treatment area. Increased risk of ischaemia in areas w/ limited collateral blood flow. Immediately stop inj in case of changes in vision, signs of stroke, blanching of the skin, or unusual pain during or shortly after the procedure. Do not overcorrect (overfill) a contour deficiency. Do not inj into the red area of the lip (vermillion). Increased bruising, haematoma, or localised bleeding at inj site in patients w/ bleeding disorders or patients using substances that affect platelet function, thrombolytics or anticoagulants. Risk of contour irregularities & palpable lumps if injected too superficially, or in facial areas w/ thin skin eg, periorbital area. Risk of reactivation of latent or subclinical herpes viral infections. Caution in patients on immunosuppressive therapy. Should not be used in patients w/ known history of or susceptibility to keloid formation or hypertrophic scarring. Risk of inflammation at the implant site if laser treatment, chemical peeling or any other procedure based on active dermal response is performed after treatment w/ Sculptra; or if Sculptra is administered before skin has completely healed after such a procedure. Avoid excessive sun, UV lamp exposure & extreme temp until any initial swelling & redness has resolved. Safety for use during pregnancy, in breastfeeding women or in patients <18 yr has not been established.
Sign Out
